IRIDEX (IRIX) vs iTonic (ITOC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IRIDEX (IRIX) has outperformed iTonic (ITOC) over the past year, losing 52.2% versus a loss of 82.0%. iTonic is the larger company by market cap ($11.6 million vs $7.9 million), about 1.5 times the size. IRIDEX converts more of its revenue into profit, with a net margin of -8.4% versus -974.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRIX | ITOC |
|---|---|---|
| Share price | $0.4449 | $1.59 |
| Market cap | $7.92M | $11.63M |
| 1-day change | -4.59% | +6.00% |
| YTD return | -60.97% | -76.40% |
| 1-year return | -52.16% | -81.96% |
| 5-year return | -93.18% | — |
| EPS (TTM) | $-0.19 | $-4.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $52.67M | $523.03K |
| Revenue growth (YoY) | +8.23% | +16.70% |
| Net income (latest FY) | $-4.44M | $-5.10M |
| Gross margin | 36.50% | 62.59% |
| Operating margin | -4.88% | -991.71% |
| Net margin | -8.42% | -974.68% |
| 52-week high | $1.65 | $18.40 |
| 52-week low | $0.4296 | $1.40 |
| Distance from 52-week high | -73.04% | -91.36% |
| Analyst consensus | none | — |
| Avg. price target upside | +518.12% | — |
| Average volume | 385.76K | 42.84K |
| Shares outstanding | 17.81M | 6.84M |
| Employees | 93 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRIX has outperformed ITOC by 29.8 percentage points over the past year.
- IRIDEX is more profitable, keeping -8.4 cents of every revenue dollar as net income versus -974.7 cents for iTonic.
- iTonic grew revenue faster in its latest fiscal year (+16.70% vs +8.23%).
About IRIDEX
IRIX stock →IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 93 employees
About iTonic
ITOC stock →iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 7 employees
IRIX vs ITOC FAQ
Which is bigger, IRIDEX or iTonic?
iTonic (ITOC) is larger, with a market capitalization of $11.63M compared with $7.92M for IRIDEX (IRIX).
Which stock has performed better over the past year, IRIX or ITOC?
IRIX returned -52.16% over the past 12 months, compared with -81.96% for ITOC (price return, excluding dividends). Past performance does not predict future results.
Are IRIDEX and iTonic in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.